25-Jan-2019
Dengue Pipeline Insights Report, 2019 - Developmental Stage, Product Type, Molecule Type, and Administration Route - ResearchAndMarkets.com
The "Dengue - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Dengue - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Dengue development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
Descriptive coverage of pipeline development activities for Dengue
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Dengue
The report assesses the active Dengue pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the report
Companies Mentioned
- The report provides a snapshot of the pipeline development for the Dengue
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Dengue
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Dengue
- The report also covers the dormant and discontinued pipeline projects related to the Dengue
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/39m22l/dengue_pipeline?w=4
- Sanofi Pasteur
- GlaxoSmithKline
- Takeda
- GeneOne Life Science Inc.
- Abivax SA
- Agilvax Inc
- Altravax Inc
- Biological Mimetics Inc
- Bioneer Corp
- Biotron Ltd
- Codagenix Inc
- Emergent BioSolutions Inc
- Ennaid Therapeutics LLC
- GeneSegues Inc
- GlaxoSmithKline Plc
View source version on businesswire.com: https://www.businesswire.com/news/home/20190125005377/en
Lazy $1500 for the report.
- Forums
- ASX - By Stock
- BIT
- $10 Billion Deal
$10 Billion Deal, page-1287
-
- There are more pages in this discussion • 12,038 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1050263 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 0.019 |
10 | 1774771 | 0.018 |
8 | 927388 | 0.017 |
12 | 3258350 | 0.016 |
10 | 1205000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 1050263 | 5 |
0.021 | 555000 | 2 |
0.022 | 997769 | 4 |
0.023 | 1449422 | 4 |
0.024 | 153949 | 2 |
Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |